- Revenue growth over the same period last year20.4%, after deducting non-owners, the net profit attributable to the owners of the company increased by about 34.4% over the same period last year.

ShenzhenAugust 30, 2022/ PR Newswire /-- August 30, 2022, the leading cardio-cerebrovascular and peripheral vascular intervention medical device company, first Health Technology Corporation (the "Company" or "first Health Technology") and its subsidiaries (collectively referred to as the "Group") announced their unaudited consolidated results for the six months ended June 30, 2022 (the "reporting period").

Adhere to the development of "innovation" and "internationalization", and record steady growth.

In the first half of 2022, the Group continued to develop steadily under the guidance of "innovation" and "internationalization" development strategy, and actively responded to the severe challenges posed by the continuous and repeated epidemic of COVID-19 in some regions. During the reporting period, the Group realized revenue of about RMB 555.2 million, an increase of about 20.4% over the same period in 2021, and a gross profit of about RMB 441.6 million, an increase of about 17.9% over the same period last year. If non-recurrent items are excluded, that is, "and investment Ally Bridge Group Innovation Capital Partners Ⅲ, L.P." For other losses arising from financial assets at fair value included in profit or loss and "share-based payment expenses", the net profit attributable to the owners of the Company is approximately RMB 247.9 million, an increase of about 34.4% over the same period last year. Taking into account the impact of these non-recurrent items, the net profit attributable to the owners of the Company is approximately RMB214.8 million, an increase of about 5.1% over the same period last year.

Domestic business continues to climb, and overseas markets develop steadily.
In the first half of 2022, mainland China is still our largest market. Thanks to the effective marketing strategy adopted by the company and actively responding to the challenges of the adverse factors brought about by the COVID-19 epidemic in the first half of the year, domestic sales increased by about 19.3% over the same period last year, accounting for about 83.2% of the Group's total revenue.

During the reporting period, the Group continued to connect the world with innovative products and continued to enhance the brand awareness and influence of its products. With the continuous promotion of a sound international development strategy, the Group's sales from overseas markets increased by about 26.4% over the same period last year.

The three core businesses show resilience.

1) structural heart disease business:

The Group's structural heart disease business mainly includes third-generation congenital heart disease occluders and left atrial appendage occluders. During the reporting period, the sales revenue of the Group's structural heart disease business increased by about 22.5% over the same period last year to about RMB 194.9 million.

Xianjian Technology is committed to promoting and selling third-generation congenital heart disease occluder products according to local treatment needs and economic levels in the global market. A diversified product portfolio brings differentiated market advantages. Compared with the same period last year, revenue generated from the sale of congenital heart disease occluders increased by about 30.8%, while sales of third-generation congenital heart disease occluders HeartR ™, Cera ™and CeraFlex ™increased by about 9.1%, 42.6% and 34.6%, respectively. During the reporting period, the Group continued to actively promote the access of LAA occluders in the global market and hospital penetration, and sales revenue increased by about 13.1% over the same period last year.

2) Peripheral vascular disease business:

The Group is committed to providing technology-leading comprehensive interventional instruments for the treatment of peripheral vascular diseases. at present, the main products sold include thoracic aortic stent, abdominal aortic stent, iliac artery bifurcation stent and vena cava filter. During the reporting period, the Group's peripheral vascular disease business recorded sales revenue of about 316.6 million yuan, an increase of about 10.4% over the same period last year, with the market share of covered stents and vena cava filters leading in China. Sales revenue recorded an increase of about 13.9% and a decrease of about 10.1% respectively over the same period last year.

3) pacing electrophysiological business:

The Group is the first manufacturer in China with a complete product portfolio of implantable pacemakers with world-class technology and functions. In cooperation with the world's top technology and taking advantage of China's import substitution, the Group's pacing electrophysiology business continued to achieve strong growth during the reporting period, with sales revenue of about 43.7 million yuan, an increase of about 187.5% over the same period last year. The sales revenue of its main core products, implantable pacemakers and implantable pacemaker leads, increased by about 218.2% and 32.6% respectively.

Innovation-driven development pipeline is progressing smoothly

Independent innovation has injected a steady stream of vitality into the development of the Group, which can not only maintain its long-term competitiveness, but also provide better disease treatment solutions to patients around the world. In the first half of 2022, the company continued to improve its innovation ability, accelerated the research and clinical process of innovative products, and achieved the following results:

Innovative products approved for listing

• The Fitaya ™vena cava filter system is approved for registration by NMPA. This product is a new generation of vena cava filter system that has been comprehensively upgraded on the basis of the clinical application of Aegisy ™, the first vena cava filter in the Chinese market for nearly 20 years, and brings better device solutions for the majority of patients.
• The FemCross ™35 peripheral balloon dilatation catheter has been registered and approved by NMPA, further enriching the company's product layout in the field of peripheral vascular diseases.

Clinical research is progressing smoothly.

• Absnow ™Absorbable Atrial Septal defect Occlusion system is undergoing Registration approval in China
• The world's first aortic covered stent system developed for "Chimney Technology" (including Ankura ™Pro aortic stent system and Longuette ™aortic branch stent system) has completed an one-year clinical follow-up in China.
• G-Branch ™thoracoabdominal aortic stent system, the world's first aortic arch stent system developed for "windowing technology" (including Ankura ™Plus aortic arch main stent system and CSkirt ™aortic arch branch stent system) and Futhrough ™aortic stent rupture system have entered the premarket clinical stage in China.
• The IBS Angel ™Iron-based Absorbable Stent system, the world's only iron-based absorbable stent for children, has been approved for "compassionate use" by FDA in the United States and has been successfully implanted. At the same time, the product is conducting pre-market clinical trials in China.
• The IBS ™absorbable drug-eluting coronary stent system has received implied permission to conduct a confirmatory clinical trial in China, which is well under way.
• The KONAR-MF ™ventricular septal defect occluder was successfully implanted in Showa University Hospital in Japan, which is the first implantation and clinical application of our products in Japan.

Scientific and technological innovation stimulates vitality and intellectual property rights escort

Intellectual property is an important intangible asset of the Group and an important internal driving force for the Group to continuously enhance its core competitiveness in the global market for medical devices. Through continuous intellectual property innovation, application, protection and management, Qianjian Technology has formed a leading technological innovation capability, a forward-looking patent layout and a sound intellectual property protection system. As of June 30, 2022, the Group has submitted a total of 1567 valid patent applications, of which 668 valid patents have been approved.

Promote project cooperation and expand the dimension of future development

Quickly enter the field of tumor intervention through strategic cooperation

The company established Dongguan Xianjian Quantum Medical Technology Co., Ltd together with ABG Innovation-Quantum Limited and Quantum Surgical SAS in 2019 to focus on the R & D and commercialization of designated products (including tumor intervention integrated robot platform and its upgraded version) in China. The innovative surgical robot completed type inspection and submitted an application for registration in China in 2021 and is currently in the process of examination and approval.

Deepen the strategic cooperation of pacemakers and open a new era of nuclear magnetic compatible pacing made in China

In 2021, the Company signed a series of supplementary agreements with Medtronic PLC to further expand the strategic cooperation of the "Xintong" domestic pacemaker project, adding nuclear magnetic compatible pacemakers and nuclear magnetic compatible wires to the range of cooperative products. this will strengthen the strategic cooperation between the Company and Medtronic PLC in pacemakers and opportunities to further deepen cooperation in the future. During the reporting period, the product is undergoing type inspection.

Looking to the future, Mr Xie Yuehui, Chairman and Chief Executive Officer of Xianjian Technology, said:

"despite the challenging external environment in the first half of 2022, we are still moving forward steadily in R & D, innovation and international development, bringing steady growth to our performance. Looking to the future, we will further consolidate the two core development strategies of "innovation" and "internationalization" and continue to promote the steady and rapid development of our existing business in the global market with leading technology, excellent quality and global sales channels. consolidate and continuously enhance the global market share of our products and the Group's international influence. At the same time, we will actively seek and seize new development opportunities with a view to achieving our ambitious goals in the field of global health at an early date. "

About Xianjian Technology:

Xianjian Technology Co., Ltd. (stock code: 1302.HK) is a leading cardio-cerebrovascular and peripheral vascular intervention medical device enterprise, founded in Shenzhen, China in 1999, is a national high-tech enterprise, the Ministry of Industry and Information Technology specializes in the new "Little Giant" enterprise. The company is researching and selling products covering structural heart disease, peripheral vascular disease, pacing electrophysiology, respiratory intervention, nerve intervention, tumor intervention and other fields, and has the world's first iron-based bioabsorbable material platform to achieve independent innovation in many fields. A total of 14 products have been approved by the State Drug Administration (NMPA) to enter the "Special Review procedure for innovative Medical Devices". Achieve high-quality patent layout of more than 1500. The market share of the company's main products for sale has been in the leading position in China for a long time. At present, the sales network has gone deep into more than 100 countries and regions around the world. It is a rare domestic medical device enterprise with highly international business.